News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Genzyme Corporation (GENZ) Recognized As A Top Employer By Scientists For Second Consecutive Year

10/19/2005 5:12:19 PM

CAMBRIDGE, Mass., Nov. 29 /PRNewswire-FirstCall/ -- Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme placed 6th among the 317 global companies included in the survey, rising from 10th place last year.

The survey, which was commissioned by the journal, Science, and the American Association for the Advancement of Science (AAAS), identifies the top 20 companies with the best reputations as employers. More than 1,100 Science readers participated in the survey.

"To be regarded among the very best life science employers is a great honor," said Alan Smith, Ph.D., sr. vice president of research and chief scientific officer at Genzyme. "Genzyme's commitment to helping patients with debilitating diseases pervades everything we do, and is a large part of what makes this company an exciting and rewarding place for scientists to work. Our scientists' efforts can lead to dramatic improvements in human health, and this infuses their work with a strong sense of meaning and purpose."

The survey was conducted from April 13 to May 10, 2004. Science subscribers were invited to respond to the survey, and asked to submit the names of companies they considered the best, average and worst employers.

The respondents then rated those companies on 42 different attributes from seven categories. The categories included corporate image, leadership and direction, financial prowess, work culture/environment, work/life balance, academics and collegial exchange, and compensation and benefits.

Examples of specific attributes include whether the company treats employees with respect, whether work-culture values are aligned with employees' personal values, and whether the company has a clear vision of the future. Of the companies included in the survey, Genzyme earned the highest rating for social responsibility.

"Genzyme works to make a positive impact on both the global and grassroots levels," said Smith. "The company provides free medicine to patients in more than 17 developing countries, and supports science education and health initiatives in the communities in which it operates. Genzyme's corporate headquarters is one of the most environmentally responsible office buildings in the United States, and the company is a leader in waste-reduction and recycling efforts at its sites around the world."

Scientists working at Genzyme are developing new and next-generation therapies in five major medical areas using a wide range of technologies. The company is bringing new treatments to patients with genetic diseases, kidney disease, cancer, orthopedic problems, and transplant and immune diseases.

More than 1,500 people are employed in research and development positions at Genzyme. The company's primary research and development facilities are in Massachusetts. Genzyme this year opened its European center for discovery research in Cambridge, U.K., the top biotechnology cluster in Europe.

"We are pleased this study confirms that scientists continue to regard us highly as an employer," said Zoltan Csimma, sr. vice president of human resources. "At Genzyme we believe that every individual has the power to make a difference. This principle coupled with the broad range of opportunities we offer plays a critical factor in our success in attracting and retaining talented people in all areas of science."

The survey results appear in a special supplement to the November 26 issue of Science. Copies of the ranking are available through the AAAS Office of Public Programs, (202) 326-6440,

For information about other recognition Genzyme has received, please visit

About Genzyme

Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services, and sophisticated biomaterials. Genzyme's commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. Approximately 7,000 Genzyme employees in offices around the globe serve patients in more than 80 countries.

About AAAS

The American Association for the Advancement of Science is the world's largest general scientific society, and publisher of the journal, Science ( AAAS was founded in 1848, and includes some 262 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of one million. The non-profit AAAS ( is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy; international programs; science education; and more.

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.

Media Contact: Erin Emlock (617) 768-6923

Genzyme Corporation

CONTACT: Erin Emlock of Genzyme, +1-617-768-6923

Read at

comments powered by Disqus